STRATEGY
Pharma and BiotechIs it possible to continue growing?
While the industry still performs on a high level, growth prospects are not as they had been in the past.
Joachim M Greuel
Founding and Managing Partner, Bioscience Valuation BSV GmbH
|
Finding the Way in ChinaCritical issues for partnership and investment
Multinational pharmaceutical companies are rushing to China with an aim to access the low-cost scientific talent and also claim a stake in Asia's largest pharmaceutical market. But the Chinese business climate is far from what one normally encounters in the West.
Mark J Benedyk
Head, La Jolla Incubator, The Pfizer Incubator, LLC
|
RESEARCH & DEVELOPMENT
Drug DiscoveryA decentralised multi-polar model
Where the pharmaceutical industry is being unable to successfully translate core models of drug discovery from theory to practice, the two-pronged approach of Evolva Biotech stands as a case in building a diversified and risk balanced compound pipeline.
P.Muthuswamy Murali
Shriram Raghavan
Managing Director
Head of Compound Development
Evolva Biotech Private Limited
|
The Asian Vaccine IndustryOpportunities and challenges
A roadmap for Asian vaccine research and development programmes can lead to a strong regional vaccine industry, self-sufficient healthcare policy and the possibility of economic growth through the manufacturing of valuable biological products.
Pele Choi-SingChong
Investigator and Director, Vaccine Research and Development Center, National Health Research Institutes
|
Controlling Infectious DiseasesEvaluation of vaccines
Although vaccine evaluation differs in various aspects from that for therapeutic drugs, many procedures specific for therapeutic drugs have been applied to vaccine evaluation.
Yoshinobu Horiuchi
Head, Laboratory of Pertussis and Endotoxin Control, National Institute of Infectious Diseases
|
Developing Cancer VaccinesUsing tumour-associated peptides
Effective next-generation cancer vaccines have to include relevant and well characterised antigens known to be presented by real tumour tissue.
Harpreet Singh
Toni Weinschenk
Managing Director and Chief Scientific Officer
Head of Discovery
immatics biotechnologies GmbH
|
CLINICAL TRIALS
Metabolomics Strategy Identifying tissue-specific drug effects
The maturation of metabolomics technologies is expected to have profound effect on pharmaceutical R&D. Over the past few years, technologies have matured to the stage where comprehensive and quantitative investigation of global metabolome has been made possible.
Matej Orešic
Research Professor, VTT Technical Research Centre of Finland
|
MANUFACTURING
Ready-To-Use Technologies Driving process excellence and product safety
Biopharmaceutical manufacturing processes like cell culture, harvesting and downstream purification are rapidly gaining importance as process robustness and assurance of product safety in these processes are being considered seriously.
Eric Grund
Director, FastTrak Biopharma Services, GE Healthcare
|
Lean Transformation Superficial imitation or a paradigm shift?
True innovation is not achieved by superficial imitation or the isolated or random use of lean tools & techniques and systems ("know how"), but instead requires the "know why"-i.e., an understanding of underlying principles.
Randy Cook
Brian Atwater
Jacob Raymer
Director of Education
Associate Professor, Business Administration
Assistant Director of Education
The Shingo Prize – for Operational Excellence
|
Identifying Counterfeit DrugsAn unexpected benefit of PAT / QbD
The spectroscopic signature of a product, developed for PAT, may also be used in the field to determine whether a product is real or counterfeit.
Emil W Ciurczak
Chief Technical Officer, Cadrai Technology Group
|
Anti-Counterfeiting TechnologiesWhat makes them effective?
Only a cross-functional and integrated approach can be successful in defeating counterfeiting and fraud, as well as the diversion of pharmaceutical products.
Thomas Völcker
Marketing & Sales Director, Schreiner ProSecure
|
|
